8-K: PTAB leaves 23 Seer patent claims intact

Seer reports a PTAB decision that upholds five of eleven challenged claims and leaves 23 of 29 total claims valid on its Proteograph-related patent, with appeals due by May 25, 2026.

Summary

• On March 23, 2026, the PTAB issued a Final Written Decision in inter partes review IPR2024-01473 concerning U.S. Patent No. 11,435,360 B2, which underpins Seer’s Proteograph platform.
• The petition, filed by PreOmics GmbH and Biognosys AG (Bruker subsidiaries), challenged 11 of the patent’s 29 claims (claims 1-4, 6, 7, 17, and 22-25).
• Five of the challenged claims were upheld and six were found unpatentable, leaving a total of 23 claims (the five upheld plus 18 unchallenged) valid and enforceable.
• The upheld claims include limitations relating to detecting proteins across a wide concentration range and the nature of the nanoparticles used—key to deep, unbiased proteomic analysis.
• The patent is owned by The Brigham and Women’s Hospital, Inc. and is exclusively licensed to Seer.
• Either party may appeal; notices of appeal must be filed by May 25, 2026.
• Management highlighted the decision as affirming the strength of Seer’s technology and reiterated plans to continue defending and investing in its IP.
• Seer’s broader IP portfolio comprises more than 240 issued patents and pending applications worldwide, including 80 issued patents.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as modestly positive: core claims remain enforceable and protect Seer’s platform, though the invalidation of six challenged claims and potential appeals keep legal risk elevated.

Positives

• 23 of 29 total claims remain valid and enforceable, preserving core protections for the Proteograph platform.
• Five of the eleven challenged claims were upheld, including claims tied to protein detection depth/dynamic range and particle design—critical performance aspects.
• Exclusive license from The Brigham and Women’s Hospital secures Seer’s control over the patent.
• Seer cites a broad IP portfolio (240+ issued patents and pending applications worldwide, including 80 issued patents), supporting long-term defensibility.

Negatives

• Six of the challenged claims were found unpatentable, narrowing aspects of the patent’s scope.
• Potential for continued legal proceedings and associated uncertainty pending any appeal before the May 25, 2026 deadline.

Risks

• Either party may appeal the PTAB decision; notices of appeal are due by May 25, 2026.
• Forward-looking statements acknowledge uncertainty around the strength and scope of the IP portfolio and Seer’s ability to protect its innovations and market position.
• Seer may pursue additional legal options, indicating ongoing IP-related legal processes.

Future Outlook

Management intends to continue defending and investing in its intellectual property and may pursue available legal options, while noting that either party could appeal the PTAB decision by May 25, 2026.

Management Comments

• “The PTAB’s decision affirms the strength of our technology and our Proteograph platform.” — Omid Farokhzad, Chair and CEO (paraphrased)
• Seer plans to continue to defend and invest in the IP that protects its technology and supports delivery of deep, reproducible, scalable proteomics data (paraphrased).

Industry Context

StockSavvy.ai notes that proteomics tools vendors increasingly rely on IP to defend differentiated sample-prep and analysis workflows. A mixed PTAB outcome that leaves a substantial portion of claims valid is common in life-science tools disputes and should help Seer maintain product positioning versus Bruker-affiliated challengers, while some narrowing of claims may modestly elevate competitive and legal uncertainty.

Comparison to Industry Standards

• Partial patent claim survival in PTAB reviews is typical in life-science tools; outcomes similar to 10x Genomics’ various IPR and district court skirmishes where some claims survive and others are narrowed.
• Compared with high-profile outcomes (e.g., Illumina vs. BGI) where broader invalidations or injunctions materially shifted competitive dynamics, Seer’s mixed result appears more moderate, preserving key functionality claims tied to performance (depth/dynamic range) and particle design.
• Versus peers in proteomics workflows (e.g., Bruker ecosystem, Thermo Fisher-affiliated sample-prep partners), maintaining enforceable core claims supports Seer’s freedom-to-operate and differentiation, albeit with a narrowed claim set.

Legal Proceedings

• PTAB Final Written Decision (March 23, 2026) in IPR2024-01473 regarding U.S. Patent No. 11,435,360 B2; 11 claims were challenged by PreOmics GmbH and Biognosys AG (Bruker subsidiaries).
• Five challenged claims were upheld and six were found unpatentable, leaving 23 of 29 total claims valid and enforceable.
• Either party may appeal; notice of appeal must be filed by May 25, 2026.

Stakeholder Impact

• Shareholders: Maintains meaningful patent protection for core technology, reducing IP overhang though some claim scope was narrowed.
• Customers: Supports continuity and defensibility of Proteograph-based workflows in research settings.
• Competitors (including Bruker subsidiaries): Must navigate remaining valid claims, but invalidated claims may open limited avenues for design-around.
• Licensor (The Brigham and Women’s Hospital): Preservation of substantial claim coverage sustains licensing value.

Next Steps

• Determine whether to file a notice of appeal by May 25, 2026.
• Continue to defend and invest in intellectual property protecting the Proteograph platform.
• Monitor for any appeal by petitioners (PreOmics GmbH and Biognosys AG).

Key Dates

Recommendation

The outcome is mixed but stabilizing: substantial claim coverage remains in force to support Seer’s Proteograph platform, yet six challenged claims were invalidated and an appeal window remains open. Without financial updates or clearer competitive ramifications, a neutral hold is warranted pending any appeal developments and operational execution.

Keywords

Seer, PTAB, inter partes review, IPR2024-01473, U.S. Patent 11, 435, 360, Proteograph, proteomics, nanoparticles, protein enrichment, PreOmics, Biognosys, Bruker, intellectual property, patent decision, mass spectrometry sample prep